Can bacteremia due to glycopeptide-susceptible Enterococcus faecium be treated with linezolid?
Linezolid versus glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteremia: A propensity-score matched comparative study.
Rédigé par : Dr Philippe Lesprit
Vancomycin is the first-line treatment of glycopeptide (GP)-susceptible E. faecium (GSEF)-bloodstream infections (BSI) except for the rare amoxicillin-sensitive strains. GP have many disadvantages: slow bactericidal activity, toxicity and complex administration procedures requiring plasma concentrations monitoring. Alternatives would therefore be useful and linezolid (LNZ) could be a suitable c...
Ce contenu est à destination des professionnels de santé. Merci de vous identifier.
This content is intended for healthcare professionals. Thank you for identifying yourself.
This content is intended for healthcare professionals. Thank you for identifying yourself.
Déjà inscrit / Already registered ?
Créer un compte / Create an account
Créer un compte ne prend que quelques minutes et vous permettra d'accèder à l'ensemble des contenus du site.
Creating an account takes only instant and will allow you to access all the content of the website.